{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:14Z","timestamp":1793640674306,"version":"4.5.1"},"reference-count":15,"publisher":null,"issue":"8","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    To evaluate changes in 12-lead ECG in patients with coronavirus infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Materials and methods<\/jats:italic>\n                    This article describes signs of electrocardiographic right ventricular \u201cstress\u201d in patients with COVID-19. 150 ECGs of 75 COVID-19 patients were analyzed in the Institute of Cardiology of the National Medical Research Centre for Therapy and Preventive Medicine. The diagnosis was based on the clinical picture of community-acquired pneumonia, data of chest multispiral computed tomography, and a positive test for COVID-19. ECG was recorded both in 3-6 and in 12 leads. Signs of right ventricular (RV) stress, so-called systolic overload (high R and inverted T\n                    <jats:sub>V1\u20133<\/jats:sub>\n                    and T\n                    <jats:sub>II, III, aVF<\/jats:sub>\n                    ), and diastolic overload (RV wall hypertrophy and cavity dilatation; complete or incomplete right bundle branch block) were evaluated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results<\/jats:italic>\n                    The most common signs for impaired functioning of the right heart include emergence of the RV P wave phase (41.3\u200a%), incomplete right bundle branch block (42.6\u200a%), ECG of the S\n                    <jats:sub>I<\/jats:sub>\n                    Q\n                    <jats:sub>\u2008III<\/jats:sub>\n                    T\n                    <jats:sub>III<\/jats:sub>\n                    type (33.3\u200a%) typical for thromboembolic complications, and signs of RV hypertrophy, primarily increased S\n                    <jats:sub>V5\u20136<\/jats:sub>\n                    (14.7\u200a%). These changes are either associated with signs of RV myocardial stress (16\u200a%) or appear on the background of signs for diffuse hypoxia evident as tall, positive, sharp-ended T waves in most leads (28\u200a%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion\u00a0\u00a0\u00a0\u00a0\u00a0<\/jats:italic>\n                    A conclusive, comprehensive assessment of the reversal of hemodynamic disorders and electrocardiographic dynamics in patients with COVID-19 will be possible later, when more data become available.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2020.8.n1192","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T09:30:55Z","timestamp":1604655055000},"page":"16-22","source":"Crossref","is-referenced-by-count":8,"title":["ECG changes in COVID-19"],"prefix":"10.68900","volume":"60","author":[{"given":"G. V.","family":"Ryabykina","sequence":"first","affiliation":[{"name":"National Medical Research Center for Cardiology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"ref1","unstructured":"Ministry of Health of Russian Federation. Temporary guidelines of the Ministry of health of the Russian Federation \u201cPrevention, diagnosis and treatment of new coronavirus infection (COVID-19)\u201d. Version 3. (03.03.2020). Moscow. Av. at: https:\/\/www.garant.ru\/ products\/ipo\/prime\/doc\/73647088\/. 2020."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;105949. [Epub ahead of print]. DOI: 10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cheung CC, Davies B, Gibbs K, Laksman ZW, Krahn AD. Multi-lead QT Screening is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era. JACC: Clinical Electrophysiology. 2020;S2405500X20302504. [Epub ahead of print]. DOI: 10.1016\/j.jacep.2020.04.001","DOI":"10.1016\/j.jacep.2020.04.001"},{"key":"ref4","unstructured":"Ryabykina G.V., Blinova E.V., Sakhnova T.A. Electrovectorcardiographic diagnosis. In \u201cPulmonary Hypertension\u201d ed. I.Ye. Chazova, T.V. Martynyuk. - M.: Publishing House Praktika. 2015;155\u2013188. ISBN 978-5-89816-138-5]"},{"key":"ref5","unstructured":"Beresten N.F., Sandrikov V.A., Fedorova S.I. Functional diagnostics. National guidelines. Chapter 2. -M.: GEOTAR-Media;2019. \u2013784 p. ISBN 978-5-9704-4242-5"},{"key":"ref6","unstructured":"Tomov L., Tomov I. Heart rhythm disturbances. -M.: Medicine and physical education;1976. - 390 p."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yan G-X, Antzelevitch C. Cellular Basis for the Brugada Syndrome and Other Mechanisms of Arrhythmogenesis Associated With ST-Segment Elevation. Circulation. 1999;100(15):1660\u20136. DOI: 10.1161\/01.CIR.100.15.1660","DOI":"10.1161\/01.CIR.100.15.1660"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Alings M, Wilde A. \u201cBrugada\u201d Syndrome: Clinical Data and Suggested Pathophysiological Mechanism. Circulation. 1999;99(5):666\u201373. DOI: 10.1161\/01.CIR.99.5.666","DOI":"10.1161\/01.CIR.99.5.666"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gussak I, Antzelevitch C, Bjerregaard P, Towbin J, Chaitman B. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. Journal of the American College of Cardiology. 1999;33(1):5\u2013 15. DOI: 10.1016\/S0735-1097(98)00528-2","DOI":"10.1016\/S0735-1097(98)00528-2"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zhang J, Sacher F, Hoffmayer K, O\u2019Hara T, Strom M, Cuculich P et al. Cardiac Electrophysiological Substrate Underlying the ECG Phenotype and Electrogram Abnormalities in Brugada Syndrome Patients. Circulation. 2015;131(22):1950\u20139. DOI: 10.1161\/CIRCULATIONAHA.114.013698","DOI":"10.1161\/CIRCULATIONAHA.114.013698"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I et al. Cardiac Histological Substrate in Patients With Clinical Phenotype of Brugada Syndrome. Circulation. 2005;112(24):3680\u20137. DOI: 10.1161\/CIRCULATIONAHA.105.520999","DOI":"10.1161\/CIRCULATIONAHA.105.520999"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Coronel R, Casini S, Koopmann TT, Wilms-Schopman FJG, Verkerk AO, de Groot JR et al. Right Ventricular Fibrosis and Conduction Delay in a Patient With Clinical Signs of Brugada Syndrome: A Combined Electrophysiological, Genetic, Histopathologic, and Computational Study. Circulation. 2005;112(18):2769\u201377. DOI: 10.1161\/CIRCULATIONAHA.105.532614","DOI":"10.1161\/CIRCULATIONAHA.105.532614"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Takagi M. Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent arrhythmogenic substrates in patients with the Brugada syndrome. European Heart Journal. 2001;22(12):1032\u201341. DOI: 10.1053\/euhj.2000.2424","DOI":"10.1053\/euhj.2000.2424"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Chang D, Saleh M, Garcia-Bengo Y, Choi E, Epstein L, Willner J. COVID-19 Infection Unmasking Brugada Syndrome. HeartRhythm Case Reports. 2020;6(5):237\u201340. DOI: 10.1016\/j.hrcr.2020.03.012","DOI":"10.1016\/j.hrcr.2020.03.012"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 2020;75(23):2950\u201373. DOI: 10.1016\/j.jacc.2020.04.031","DOI":"10.1016\/j.jacc.2020.04.031"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1192\/774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:45Z","timestamp":1793639805000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,9,7]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.8.n1192","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}